A monoclonal antibody (904) that binds to a leukocyte cell adhesion-promoting glycoprotein, (Mol; CD11b/CD18) was administered (1 mg/kg, iv.) to open chest anesthetized dogs 45 min after the induction of regional myocardial ischemia. Ischemia was produced by occluding the left circumflex coronary artery (LCX) for 90 min and then reperfusing for 6 h. There was no difference between control and antibody treated groups with respect to arterial blood pressure, heart rate, or LCX blood flow. Administration of antibody produced no observable effect on circulating neutrophil counts, suggesting that antibody-bound neutrophils were not cleared from the circulation. The mean size of myocardial infarct expressed as percentage of the area at risk of infarction that resulted was reduced by 46% with anti-Mol treatment (25.8±4.7%, n = 8) compared to control (47.6±5.7%, n = 8; P < 0.01). The area at risk of infarction was similar between groups. Circulating (serum) antibody excess was confirmed in all 8 anti-Mol treated dogs by immunofluorescence analysis. Analysis of ST segment elevation on the electrocardiogram as an indicator of the severity of ischemia suggests that the anti-Mol reduces infarct size independent of the severity of ischemia. An additional group of dogs (n = 5) was tested with a control monoclonal antibody of the same subtype (murine IgGI) and was found to produce no significant reduction in myocardial infarct size. Accumulation of neutrophils within the myocardium was significantly attenuated with 904 treatment when analyzed by histological methods. These data demonstrate that administration of anti-Mol monoclonal antibody after the induction of regional myocardial ischemia results in reduced myocardial reperfusion injury as measured by ultimate infarct size.
Introduction
Mo 1 (CD 11 b/CD 18) is a heterodimeric glycoprotein expressed on the plasma membrane of human neutrophils, mononuclear phagocytes, and null cells (1) . It consists of two noncovalently linked polypeptides of 155,000 D (the alpha subunit) and 94,000 D (the beta subunit) (2) . Monoclonal antibodies specific for either the alpha or beta subunits of Mol have been demonstrated to inhibit certain neutrophil/monocyte functions: (a) the binding of C3bi-opsonized particles (3) , and (b) adhesive interactions of neutrophils and monocytes including neutrophil aggregation, monocyte/neutrophil adhesion and spreading on substrates (including vascular endothelium), and chemotaxis (4) (5) (6) (7) (8) . The leukocytes of individuals who are genetically deficient in their expression of the Mol glycoprotein exhibit an impairment of C3bi-particle binding and leukocyte adhesive interactions (9, 10) . These observations indicate that the Mo 1 glycoprotein has at least two functional domains: (a) a domain that functions as the plasma membrane receptor for C3bi (CR3), and (b) a domain that promotes the adhesion of myeloid leukocytes (7) . Other studies have indicated that exposure of neutrophils and monocytes to inflammatory stimuli in vitro and in vivo results in marked increase in surface Mo 1 expression that is coincident with an increase in leukocyte adhesiveness (1 1, 12) . The critical role of Mo 1 in the inflammatory response of activated neutrophils is suggested by the inhibitory effect of anti-Mo 1 monoclonal antibody on neutrophil-mediated endothelial cell injury in a rat lung model of adult respiratory distress syndrome (ARDS)' (13) and neutrophil-dependent vascular injury in skin (14) .
A substantial and convincing body of evidence indicates that neutrophils cause damage to the heart when the heart has been subjected to a period of regional ischemia and reperfusion. Studies have demonstrated that if dogs are depleted of circulating granulocytes with a neutrophil specific antiserum (15) or nitrogen mustard (16) before the induction of regional myocardial ischemia and reperfusion, the size of myocardial infarct that results is significantly smaller than in dogs with normal circulating neutrophil counts. There are a number of other studies that have shown that agents that inhibit neutrophil activation and accumulation within the myocardium also result in reduced myocardial infarct size (16) (17) (18) (19) (20) .
In a previous report, we have identified a specific monoclonal antibody (904) that binds to the alpha subunit (CD I I b) of both dog and human leukocyte Mol (7, 21, 22) . Antibody 904 is specific for an epitope within the adhesion-promoting domain of Mo 1 (7) and inhibits neutrophil (dog and human) aggregation in vitro stimulated by leukoaggregating factors (phorbol myristate acetate and formyl-methionyl-leucyl-phenylalanine, respectively). The purpose ofthis investigation was to determine whether in vivo administration of this monoclonal antibody to dogs 45 min after the induction of regional myocardial ischemia would effectively reduce myocardial injury upon subsequent reperfusion of the myocardium.
Methods
Monoclonal antibody. The generation of the murine IgGI anti-Mo 1 monoclonal antibody (clone 904) was described elsewhere (7, 21) . The antibody binds to an epitope on the CDl lb, 1 55-kD alpha polypeptide of the Mol glycoprotein that is expressed in both human and dog neutrophils (7, 21, 22) . Pharmaceutical-grade anti-Mol monoclonal antibody was supplied by Coulter Immunology (Hialeah, FL) and was purified from aseptically collected murine ascites by ammonium sulfate precipitation and protein A affinity chromatography. Sterile-filtered antibody was diluted to a concentration of 5 mg/ml in PBS containing either 0.5 or 5% (wt/vol) normal human serum albumin (HSA diluent). The endotoxin level of the two 904 antibody lots used were 1.92 EU/mg and 1.54 EU/mg; the corresponding endotoxin levels ofthe two HSA diluent lots employed were 0.96 EU/mg and 0. 12 EU/mg. A control murine monoclonal IgG I antibody (Ms IgGl; Coulter Immunology) was prepared in a similar fashion (endotoxin level of 0.38 EU/mg).
Preparation of dogs. Adult male mongrel dogs (12-17 kg) were anesthetized with a solution ofdial urethane (0.65 ml/kg) that contains allobarbital, 10 g/liter; urethane, 400 g/liter; and monoethylurea, 400 g/liter. Dogs were respired by positive pressure ventilation with room air. The hearts were exposed through a left thoracotomy in the fifth intercostal space and suspended in a pericardial sling. The left circumflex coronary artery was isolated from surrounding connective tissue proximal to any ventricular branches and instrumented with a calibrated electromagnetic flow probe for the continuous recording of blood flow. Catheters were placed into the aorta via the left carotid artery for blood pressure recording and into the left jugular vein for antibody infusion and blood sampling. The standard limb lead II electrocardiogram was recorded continuously.
Regional myocardial ischemia was produced by occluding the circumflex artery for 90 min and then reperfusing the myocardium in the presence of a critical stenosis (23) . The critical stenosis prevents the development of hemorrhagic infarction and reduces the incidence of reperfusion induced ventricular fibrillation. After reperfusing the myocardium for 6 h, the heart was electrically fibrillated and excised. Using the ex vivo dual perfusion histochemical staining technique previously described (15), the infarct size was assessed as a percentage ofthe area ofthe myocardium at risk of infarction as well as a percentage of the total left ventricle. This technique involves perfusion of the cannulated circumflex with 1.5% triphenyltetrazolium chloride (TPT) solution buffered with 20 mM potassium phosphate (pH 7.4), while simultaneously perfusing the remainder of the coronary circulation with Evan's blue dye introduced into the aorta. Both solutions were delivered to the respective vascular distributions under a constant pressure of 100 mmHg at a temperature of 37°C for 5 min. The hearts were then cut into five or six 1-cm thick transverse sections and infarct size was determined planimetrically. The method of quantifying infarct size with TPT has been validated by a number of investigators and has been shown to accurately demarcate viable from nonviable myocardial tissue as determined by the histochemical reaction between TPT and myocardial dehydrogenase enzymes (24) (25) (26) (27) .
Treatment groups. Initially, dogs were randomly assigned to one of two treatment groups for the assessment of anti-Mo 1 antibody on resulting myocardial infarct size. The two groups were: group I, controls, received the vehicle for the monoclonal antibody (0.5% or 5% human serum albumin); and group II, anti-Mol, received antibody (904; Coulter Immunology) 1 mg/kg infused intravenously over 10 min beginning 45 min after the induction of regional myocardial ischemia. After the results from the initial two groups were analyzed, a third group of dogs was tested in a nonrandomized fashion with five additional dogs. This third group (antibody control) consisted of five dogs that were treated with a control murine monoclonal antibody (same dose and time) of the same subclass (IgGl; Coulter Immunology) that is unreactive with the Mol glycoprotein on canine neutrophils.
Detection ofanti-Mol antibody binding to dog leukocytes. At 0, 85, and 120 min after induction of ischemia, 4-ml aliquots of venous blood were withdrawn from dogs, placed into EDTA-containing tubes, and centrifuged for 5 min at 800 g. Plasma was separated from the pellet and was saved for subsequent analysis of residual monoclonal antibody; the cellular pellet was depleted of erythrocytes by ammonium chloride lysis, and the residual leukocytes were analyzed for the presence of preexisting bound anti-Mo 1 antibody by immunofluorescence staining (1 1). Briefly, 1-2 X 106 leukocytes were incubated for 30 min at 4°C in buffer alone or in buffer containing a saturating concentration of murine anti-Mo 1 antibody. The cells were then washed and incubated for an additional 30 min at 4°C in buffer containing a saturating concentration of fluorescein-conjugated goat anti-mouse immunoglobulin (Tago, Inc., Burlingame, CA). Antibody binding (either as a result of in vivo administration of anti-Mo 1 or after in vitro exposure to additional anti-Mo 1 antibody) to dog neutrophils and monocytes was assessed by flow cytometry after selective gating on these myeloid cells (as determined by log forward angle versus log right angle light scatter) using a Coulter Epics C flow cytometer. The fluorescence intensity of 5,000 cells/determination was used as a quantitative measure of antibody binding.
Detection Fig. 1 A) . Simi Histology. The relative degree of neutrophil accumulation as determined histologically with 0 representing no cellular infiltrate and 4 representing the greatest infiltration score were as follows: Control (n = 8) 3,3,3,3,3,3,2,2; 904 antibody (n = 8)
1,1,1,2,2,2,3,4. Using nonparametric methods to draw statistical inferences (two-sample rank sum test), the 904 antibodytreated group had significantly less neutrophilic infiltrate compared to vehicle controls (P < 0.05). Circulating neutrophil counts. As illustrated, in Fig. 2 , by the control group, circulating neutrophils increase in number during the process of myocardial infarction. Treatment with anti-Mo 1 antibody markedly suppressed the early rise in circulating neutrophil count during early reperfusion. However, circulating neutrophil levels did not decrease below baseline levels after antibody treatment.
Hemodynamic effects. Mean arterial blood pressure (MAP), heart rate (HR), left circumflex (LCX) blood flow, and rate pressure product (RPP; MAP X HR/100) were measured (Fig. 3) at regular intervals during the experiments to determine whether the antibody had any effects on these parame- Figure 2 . Circulating neutrophil counts. The mean neutrophil counts were significantly less during reperfusion (*P < 0.05) in the antibody treated group suggesting that 904 was suppressing the rise in circulating counts. Additionally, the data demonstrate that neutrophils are not cleared from the circulation by treatment with antibody.
ters. The two treatment groups had similar MAP, HR, RPP, and LCX blood flow at baseline and at every time point during the experiments. Thus, the protective effects of the antibody could not be attributed to changes in myocardial blood supply (as measured by LCX blood flow) or myocardial oxygen demand (as measured by RPP or HR or MAP).
Discussion
In this report we present evidence that the intravenous administration of a monoclonal antibody (904) directed against the leukocyte adhesion promoting molecule, Mol (CDl lb/CD 18) can reduce myocardial reperfusion injury in a well characterized animal model of myocardial infarction. Previous reports have demonstrated that inhibition of neutrophil activation during myocardial infarction with agents that inhibit the fatty acid lipoxygenase enzyme (16) (17) (18) or with prostanoids (19, 20) . This study extends these observations to indicate that the adhesive interactions of the neutrophil may play a central role in neutrophil mediated damage and that inhibition of neutrophil adhesive interactions with an anti-Mo1 monoclonal antibody can reduce myocardial reperfusion injury.
Two major determinants of myocardial infarct size are the severity and the duration of the ischemic period. The results from the present study indicate that administration of the anti-Mo 1 monoclonal antibody (904) provided protection independent of the severity of ischemia as shown in Fig. 1 B. Inasmuch as the duration of ischemia was 90 min in all cases, the mechanism of protection by this antibody may be attributed to its inhibitory effects on neutrophil adhesion and spreading within the myocardium.
That the Mol glycoprotein plays a critical part in the inflammatory response of neutrophils is indicated by a number of studies in which monoclonal antibodies directed against Mol block adhesion-dependent cellular interactions. AntiMo 1 (anti-CD1 lb or anti-CD 1 8) antibodies inhibit neutrophil aggregation in response to inflammatory stimuli (6, 8, 12 ), neutrophil chemotaxis stimulated by chemotactic factors (7, 8) , and adhesion and spreading of monocytes and neutrophils on substrates including glass, plastic, and monolayers of endothelial and epithelial cells (4) (5) (6) (7) (8) 29) . Additionally, these antibodies inhibit adhesion-dependent neutrophil-mediated damage of endothelial (30) and epithelial monolayers (29) in vitro, and block pulmonary capillary injury induced by activated human neutrophils in a perfused rat lung model of ARDS (13) . It has recently been shown that anti-Mo 1 antibody (anti-CD18; antibody 60.3) can reduce neutrophil accumulation and plasma leakage in vivo in response to the intradermal injection of the complement activation product, C5a (14) and neutrophil migration to and accumulation in subcutaneously implanted sponges (31) . While certain anti-Mo 1 antibodies recognize epitopes within the CR3 binding domain of the Mo 1 glycoprotein and block CR3-dependent cellular interactions (phagocytosis, respiratory burst, and granule release stimulated by particulate activators of the alternative pathway [3, 7, 8, 32, 33] ), antibody 904 (anti-CD 1 lb) is selective in its inhibitory effect on neutrophil adhesive interactions (specific for an epitope within the adhesion-promoting domain of Mo 1 (7).
Anti-Mo 1 (904) administration in vivo significantly reduced neutrophil accumulation within ischemic myocardial tissue as assessed by histological analysis of tissue sections. These data indicate that neutrophil adhesive interactions are a very important step in neutrophil-mediated myocardial reperfusion injury and that by interfering with neutrophil adhesive interactions, tissue injury may be reduced.
The clinical implications of the present study are profound. For the first time, a neutrophil suppressive agent of great selectivity and specificity with a defined mechanism of action has been shown to be highly effective in inhibiting tissue injury in an experimental model of acute myocardial infarction. Other experimental therapies that suppress neutrophil function and reduce myocardial infarction include neutrophil depletion (15) and the administration of prostacyclin and its analogues (19, 20) . Prostacyclin and its analogues although very promising in the setting of acute myocardial infarction are not without significant side effects (vasodilation, inhibition of platelet function) and neutrophil depletion is not feasible as a therapeutic intervention. In contrast, the use of a monoclonal antibody (or F(ab')2 fragments) with selective inhibitory effects on neutrophil function offers promise for the future treatment of patients with evolving myocardial infarcts who are candidates for reperfusion by thrombolytic therapy (streptokinase, tissuetype plasminogen activator, pro-urokinase) or by mechanical (balloon angioplasty or coronary artery bypass surgery) means.
There is precedent for the therapeutic use of murine (36) . These data indicate that the use of murine monoclonal antibodies of the IgG 1 subclass directed against Mol may be without serious side effects and may be appropriate for use in humans undergoing acute myocardial infarction as well as other disease processes in which neutrophil-mediated injury is indicated.
